OVERVIEW

Our lead anti-inflammatory Lecinoxoid-based product candidate, VB-201, focuses on modifying the body’s immune-mediated native inflammatory response.  

VBL has studied VB-201 in over 600 patients and has observed it to be well-tolerated. VB-201 is covered by an issued U.S. composition of matter patent until at least 2027.

Movie_Icons-new